

Filed On Behalf Of:
Novartis Pharmaceuticals Corporation
and Breckenridge Pharmaceutical, Inc.

By:
Nicholas N. Kallas
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS PHARMACEUTICALS CORPORATION,

Patent Owner.

Case IPR2017-01592

Patent No. 8,410,131

NOTICE OF JOINT STIPULATION TO MODIFY TRIAL DUE DATE 1

Pursuant to the Board’s authorization in the January 3, 2018 Scheduling Order (Paper 13 at 2), Patent Owner Novartis Pharmaceuticals Corporation (“Patent Owner”) hereby provides notice to the Board that Patent Owner and Petitioner Breckenridge Pharmaceutical, Inc. (“Petitioner”) have stipulated to modify DUE DATE 1 as follows: DUE DATE 1 (currently set for March 28, 2018) is extended by one week to April 4, 2018.¹

Patent Owner and Petitioner agree that all other DUE DATES in the Scheduling Order remain the same.

¹ A petition for *Inter Partes* Review of U.S. Patent No. 8,410,131 and a motion for joinder to the instant proceeding are currently pending in *West-Ward Pharmaceuticals International Limited v. Novartis Pharmaceuticals Corporation*, *Inter Partes* Review No. 2018-00507 (Papers 2 and 3). Petitioner West-Ward Pharmaceuticals International Limited in that proceeding confirmed that it does not object to the above amendment of DUE DATE 1 in the instant proceeding.

Dated: February 28, 2018

Respectfully submitted,

/ Nicholas N. Kallas /

Nicholas N. Kallas

Registration No. 31,530

Lead Counsel for Patent Owner

FITZPATRICK, CELLA, HARPER
& SCINTO

1290 Avenue of the Americas

New York, NY 10104-3800

Tel. 212-218-2100

/ Daniel R. Evans /

Daniel R. Evans

Registration No. 55,868

Lead Counsel for Petitioner

MERCHANT & GOULD P.C.

191 Peachtree Street, NE,

Suite 3800

Atlanta, GA 30303

Tel. 404-954-5100

CERTIFICATE OF SERVICE

I certify that a copy of the foregoing NOTICE OF JOINT STIPULATION TO MODIFY TRIAL DUE DATE 1 was served on February 28, 2018 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Daniel R. Evans (devans@merchantgould.com)

Jeffrey D. Blake (jblake@merchantgould.com)

Melissa M. Hayworth (mhayworth@merchantgould.com)

I further certify that a copy of the foregoing NOTICE OF JOINT STIPULATION TO MODIFY TRIAL DUE DATE 1 was served on February 28, 2018 by causing it to be sent by email to counsel for Petitioner West-Ward Pharmaceuticals International Limited in *Inter Partes* Review No. 2018-00507 at the following email addresses:

Keith A. Zullo (kzullo@goodwinprocter.com)

Marta E. Delsignore (mdelsignore@goodwinprocter.com)

Dated: February 28, 2018

/ Nicholas N. Kallas /
Nicholas N. Kallas
Registration No. 31,530
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100